Risedronate or Exercise for Lean Mass Preservation During Menopause: Secondary Analysis of a Randomized Controlled Trial.

Laura E FloresKevin KupzykNancy WaltmanKristen M BeaversLaura Bilek

Published in: JCSM rapid communications (2022)

Results suggest both 12 months of oral risedronate and 12 months of weight-bearing exercise may diminish lean mass loss experienced during the menopause transition as compared to control. The lean mass sparing effect for risedronate may be driven by overall weight change.

Keyphrases

physical activity
bone mineral density
postmenopausal women
high intensity
body mass index
weight loss
resistance training
body weight
robot assisted
minimally invasive